A61K 40/32
T-cell receptors [tcr]
Official title: T-cell receptors [TCR]
A61K40/32 (T-cell receptors [tcr]) appears on 700 US grants and 1,868 published applications in this corpus.
Search patents in A61K- Granted patents
- 700
- Published applications
- 1,868
- Assignees
- 652
- Inventors
- 3,225
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 2 |
| 2002 | 1 | 11 |
| 2003 | 2 | 14 |
| 2004 | 5 | 9 |
| 2005 | 0 | 5 |
| 2006 | 4 | 13 |
| 2007 | 0 | 11 |
| 2008 | 8 | 6 |
| 2009 | 4 | 14 |
| 2010 | 9 | 16 |
| 2011 | 8 | 24 |
| 2012 | 6 | 15 |
| 2013 | 13 | 19 |
| 2014 | 7 | 30 |
| 2015 | 15 | 19 |
| 2016 | 21 | 29 |
| 2017 | 16 | 55 |
| 2018 | 25 | 75 |
| 2019 | 26 | 134 |
| 2020 | 59 | 140 |
| 2021 | 65 | 166 |
| 2022 | 54 | 217 |
| 2023 | 86 | 212 |
| 2024 | 72 | 237 |
| 2025 | 106 | 208 |
| 2026 | 85 | 187 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of isolating T cells and T-cell receptors from peripheral blood by single-cell analysis for immunotherapy6 Oct 2026US 12,753,437 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Method of treatment of cancer or tumour29 Sep 2026US 12,746,272 B2
- Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells29 Sep 2026US 12,747,292 B2Incyte Corporation
- Modulation of expression of genes related to T cell exhaustion29 Sep 2026US 12,747,431 B2The Trustees of the University of Pennsylvania
- Engineered T cell receptors and methods of use22 Sep 2026US 12,742,002 B2Board of Regents, The University of Texas System
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
- Small Molecule Based Method Of Modifying T Cells8 Oct 2026US 2026/0308520 A1Agency for Science, Technology and Research
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
Most cited
By later US patents
- CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies343US 6,410,319 B1City of Hope · 2002
- Chimeric receptor genes and cells transformed therewith196US 8,211,422 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases143US 8,956,828 B2Ospedale San Raffaele S.R.L. · 2015
- Methods of enhancing T cell responsiveness132US 7,794,710 B2Mayo Foundation for Medical Education and Research · 2010
- Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells106US 6,753,162 B1The General Hospital Corporation · 2004